Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 4/20 | 0.43 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 8/20 | 0.41 |
| ▸ | BCHE | P06276 | 7/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26492995 | 0.88 | EPHX2 (0.57) | EPHX2CNR1KDM5APHF8KDM4C | |
| SCHEMBL25317535 | 0.86 | CA2 (0.40) | EPHX2KDM5APHF8KDM4CFFAR1 | |
| SCHEMBL27384090 | 0.82 | EPHX2 (0.52) | EPHX2CNR1KDM5APHF8KDM4C | |
| SCHEMBL25318996 | 0.82 | EPHX2 (0.52) | EPHX2CNR1KDM5APHF8KDM4C | |
| SCHEMBL25319726 | 0.82 | LMNA (0.43) | EPHX2FFAR1 | |
| SCHEMBL24340301 | 0.82 | CA2 (0.46) | CNR1FFAR1 | |
| SCHEMBL29180336 | 0.82 | CA2 (0.48) | EPHX2FFAR1 | |
| SCHEMBL18665197 | 0.81 | MAPT (0.49) | EPHX2CNR1KDM5APHF8KDM4C | |
| SCHEMBL22646140 | 0.81 | MAPT (0.49) | EPHX2CNR1KDM5APHF8KDM4C | |
| SCHEMBL20892181 | 0.81 | MAPT (0.49) | EPHX2CNR1KDM5APHF8KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355527-A1 | COMPOUNDS AND COMPOSITIONS FOR DRUG DELIVERY | RNAimmune, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355527-A1 | COMPOUNDS AND COMPOSITIONS FOR DRUG DELIVERY | RNAimmune, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355527-A1 | COMPOUNDS AND COMPOSITIONS FOR DRUG DELIVERY | PLIN3, PHOSPHO1, SGMS1 | EPHX2 1216/4885CNR1 2860/4885KDM5A 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.